 |
| 20-Nov-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| 29-Aug-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| 27-Aug-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| 31-Jul-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| 24-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| 08-Apr-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| 25-Jan-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| 24-Jan-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| 12-Sep-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| 10-Sep-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
| 02-Aug-12 | Downgrade |
Argus |
Buy → Hold |
|
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Hold |
|
|
| 09-Feb-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Sep-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 10-May-11 | Reiterated |
MP Advisors |
Outperform |
$63 → $65 |
|
| 25-Apr-11 | Reiterated |
Stifel Nicolaus |
Buy |
$70 → $68 |
|
| 21-Apr-11 | Reiterated |
Oppenheimer |
Outperform |
$66 → $63 |
|
| 14-Mar-11 | Initiated |
Standpoint Research |
Buy |
$66 |
|
| 25-Jan-11 | Reiterated |
Barclays Capital |
Overweight |
$76 → $72 |
|
|
|
| 06-Dec-13 09:55AM | [video] Cramer's Six in 60: Amgen, Dollar General and more at CNBC |
| 08:30AM | The International Myeloma Foundation Announces Partnership With Onyx Pharmaceuticals to Support Black Swan Research Initiative(TM) Marketwired |
| 05-Dec-13 06:40PM | Better Earnings: Celgene, Biogen, Or Amgen? at Motley Fool |
| 04:03PM | Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference PR Newswire |
| 02-Dec-13 05:11PM | New Guideline Recommends Conservative Treatment for Heart Patients with Anemia at Forbes |
| 08:52AM | The Growing Need For Outcome Studies And The Impact On R&D Costs at Forbes |
| 07:20AM | Celgene Vs. Amgen In Multiple Myeloma Battle at Seeking Alpha |
| 01-Dec-13 12:16PM | This Week in Biotech at Motley Fool |
| 25-Nov-13 03:30PM | Bayer/Amgen's Nexavar Label Expanded Zacks |
| 12:15PM | 3 Monday Morning Biotech Movers at Wall St. Cheat Sheet |
| 12:02PM | 3 Monday Morning Biotech Movers at Wall St. Cheat Sheet |
| 01:45AM | InPlay: Amgen receives FDA approval for NEXAVAR for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment Briefing.com |
| 24-Nov-13 09:28AM | 3 New Cholesterol Treatments Worth Watching at Motley Fool |
| 22-Nov-13 08:15PM | FDA Expands Approval for Amgen's Nexavar at Motley Fool |
| 05:30PM | U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment PR Newswire |
| 04:53PM | U.S. judge throws out SEC lawsuit over 'suspicious' Onyx trading Reuters |
| 03:40PM | I'm Staying Away From Low Yielding Amgen For Now at Seeking Alpha |
| 21-Nov-13 02:50PM | Amgen shares defended at Cowen at theflyonthewall.com |
| 02:10PM | Water-Logged And Getting Wetter Stock Of The Day: Amgen (AMGN) at TheStreet |
| 01:32PM | [video] Biotech index hits an all-time high at CNBC |
| 10:50AM | Data on Amgen's Pipeline Candidates Zacks |
| 07:55AM | Eight Big Dividend Hikes Expected Before 2013 Ends at 24/7 Wall St. |
| 20-Nov-13 05:41PM | 4 Healthcare Stock Stories Waiting for Your Perusal at Wall St. Cheat Sheet |
| 09:24AM | Ahead of the Bell: Amgen's cholesterol drug AP |
| 19-Nov-13 06:15PM | Amgen cholesterol drug appears safe, cut LDL 52 pct at 1 year-study Reuters |
| 05:34PM | Amgen reports positive results from Phase 2 study of PCSK9 inhibitor theflyonthewall.com |
| 05:33PM | InPlay: Amgen announces evolocumab (AMG 145) results from first 52-week study of PCSK9 inhibitor to reduce LDL cholesterol Briefing.com |
| 05:30PM | Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol PR Newswire |
| 04:48PM | The Simplest Biotech Growth Portfolio Ever at Motley Fool |
| 04:38PM | AMGEN INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online |
| 08:44AM | Keep an Eye on BioMarin, Amgen, Merck, and AstraZeneca Today at Motley Fool |
| 18-Nov-13 05:03PM | Amgen says melanoma drug improved survival AP |
| 04:14PM | Celgene's Revlimid Faces a Tough Sell at Motley Fool |
| 04:07PM | Amgen presents survival data from Phase 3 study of talimogene laherparepvec theflyonthewall.com |
| 04:04PM | InPlay: Amgen presents interim overall survival data from Phase 3 study of talimogene laherparepvec in patients with metastatic melanoma Briefing.com |
| 04:02PM | Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma PR Newswire |
| 10:46AM | Has Myeloma Met Its Match in Amgen's Kyprolis? at Motley Fool |
| 15-Nov-13 07:51AM | Could Clinical Studies With PCSK-9 Drugs Result In Yet Another Shift In Cholesterol Guidelines? at Forbes |
| 12:01AM | New Cholesterol Drugs Face Doctors Seeking Heart Results at Bloomberg |
| 14-Nov-13 09:50PM | Questions for a New Class of Cholesterol Drugs at New York Times |
| 05:20PM | Amgen and Sanofi Drugs Can Reach U.S. Without Long Studies at Bloomberg |
| 04:03PM | Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013 PR Newswire |
| 03:42PM | Amgen and Sanofi PCSK9 Drugs Can Reach U.S. Without Long Studies at Bloomberg |
| 12:07PM | [video] MarketWatch CEO of the Year: Teslas Elon Musk at MarketWatch |
| 10:34AM | Better Buy: Biogen or Amgen? at Motley Fool |
| 07:52AM | Watch The R&D Chiefs Of Pfizer, Merck, And Amgen Discuss The Drug Industry's Challenges at Forbes |
| 13-Nov-13 10:21PM | [video] MarketWatch CEO of the Year: Teslas Elon Musk at MarketWatch |
| 12-Nov-13 09:03AM | InPlay: Amgen to highlight new evolocumab (AMG 145) data at upcoming american heart association scientific sessions 2013; first long-term data of a pcsk9 inhibitor to be featured in clinical science special reports session Briefing.com |
| 09:00AM | Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013 PR Newswire |
| 06:00AM | The Street Can't Help but Love Amgen TheStreet |
| 10-Nov-13 10:35AM | You're not a genius so sell some stock right now at MarketWatch |
| 08-Nov-13 04:15PM | Amgen To Present At The Credit Suisse Annual Healthcare Conference PR Newswire |
| 10:04AM | Ex-Dividend Reminder: Amgen, Protective Life and Duke Realty at Forbes |
| 07-Nov-13 04:42PM | InPlay: Amgen and Onyx Pharma announce upcoming data presentations at 55th American Society of Hematology Annual Meeting Briefing.com |
| 04:38PM | Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting PR Newswire |
| 09:58AM | With New Study, Scientists Try To Drag Drug Trials Into DNA Age at Forbes |
| 09:00AM | Amgen Foundation Commits $2.5 Million In New Grants To Engage 50,000 Students Each Year In The Thrill Of Scientific Inquiry PR Newswire |
| 06-Nov-13 10:55AM | InPlay: Amgen - - 50 Day Alert Briefing.com |
| 06:00AM | Roche Pacing the Field in the Biotech Race at TheStreet |
| 04-Nov-13 04:38PM | Meet the Tiny Biotech Challenging Amgen and General Electric at Motley Fool |
| 03:36PM | Your first trade for Tuesday at CNBC |
| 12:58PM | [video] FMHR Final Trade at CNBC |
| 11:41AM | [video] Five Cars the Richest Americans Are Buying at MarketWatch |
| 03-Nov-13 08:35AM | 3 Future Stars in Big Pharma's Best Pipeline at Motley Fool |
| 02-Nov-13 01:04PM | AMGEN INC Financials EDGAR Online Financials |
| 31-Oct-13 07:05AM | Array Biopharma Outlines Path To Market For New Myeloma Drug at Forbes |
| 29-Oct-13 05:23PM | AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 12:47PM | [video] Biotech is 'under-owned': Pro at CNBC |
| 11:35AM | Multiple Of 40x Earnings Gives Biogen Idec The Wobblies at Seeking Alpha |
| 28-Oct-13 08:58AM | Stada widens biotech drug offering with filgrastim licence Reuters |
| 05:29AM | The Time Has Come For Valuing ImmunoGen Technology And Pipeline Products at Seeking Alpha |
| 25-Oct-13 10:54AM | Amgen Reports Strong Numbers, But Better Days May Be Coming at Motley Fool |
| 12:01AM | [$$] Leaders in Rheumatoid Arthritis at Barrons.com |
| 24-Oct-13 03:44PM | Can AbbVie Hold Off Amgen and Pfizer? at Motley Fool |
| 12:18PM | Organovo's 3 Biggest Opportunities in 3-D Bioprinting at Motley Fool |
| 11:42AM | Celgene Earnings Beat Estimates, But Stock Dips at Investor's Business Daily |
| 08:38AM | Celgene's New Multiple Myeloma Drug Is Kicking Amgen's Ass at TheStreet |
| 08:28AM | 3 Takeaways From Amgen's Earnings Report at Motley Fool |
| 23-Oct-13 03:02PM | You're not a genius so sell some stock right now now at MarketWatch |
| 02:10PM | Amgen - Trading Around All-Time Highs As It Shifts Focus On Growth at Seeking Alpha |
| 01:17PM | You're no genius; trim stocks now at MarketWatch |
| 10:40AM | Another Earnings and Rev Beat from Amgen Zacks |
| 08:45AM | You're no genius so sell some stocks right now at MarketWatch |
| 08:08AM | Early movers: CAT, BA, JPM, NFLX, BMY, WLP & more at CNBC |
| 07:15AM | Glaxos China Sales Plunge 61% After Corruption Probe at Bloomberg |
| 22-Oct-13 09:14PM | Amgen's CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha |
| 09:03PM | You're no genius so sell some stocks right now at MarketWatch |
| 07:37PM | News Summary: Amgen 3Q profit, sales both jump AP |
| 07:34PM | On the Call: Amgen CEO Robert Bradway AP |
| 07:23PM | Amgen 3Q profit jumps 24 percent on stronger sales AP |
| 06:15PM | U.S. drug giant Amgen raises full-year revenue outlook Reuters |
| 06:00PM | U.S./Canada daily earnings hits & misses Oct 22 - 1800 ET Reuters |
| 05:49PM | Amgen 3Q profit jumps 24 pct. on stronger sales AP |
| 05:10PM | Will Amgen shares climb on word earnings, sales beat forecasts? at MarketWatch |
| 05:04PM | Amgen shares wobble after hours, Cree drops at MarketWatch |
| 05:00PM | U.S./Canada daily earnings hits & misses Oct 22 - 1700 ET Reuters |
| 05:00PM | Amgen Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:58PM | Amgen raises full-year revenue outlook Reuters |
| 04:43PM | [$$] Amgen's Profit Rises 24% at The Wall Street Journal |
| 04:34PM | Amgen 3Q profit jumps 24 pct. on stronger sales AP |
|
|
| Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Balachandran Madhavan | EVP, Operations | Sep 04 | Option Exercise | 58.43 | 18,000 | 1,051,740 | 59,133 | Sep 05 07:33 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Sale | 112.76 | 18,000 | 2,029,768 | 34,851 | Sep 05 07:33 PM | | BALTIMORE DAVID | Director | Aug 28 | Sale | 109.66 | 4,582 | 502,462 | 27,789 | Aug 30 05:36 PM | | Amgen Ventures LLC | 10% Owner | Jun 05 | Buy | 15.00 | 16,666 | 249,990 | 334,126 | Jun 05 04:01 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Option Exercise | 54.62 | 6,130 | 334,791 | 22,863 | May 24 05:18 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Sale | 104.78 | 6,130 | 642,296 | 16,733 | May 24 05:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Option Exercise | 50.44 | 6,000 | 302,640 | 46,956 | May 21 08:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Sale | 103.28 | 6,000 | 619,681 | 34,851 | May 21 08:18 PM | | HENDERSON REBECCA M | Director | May 17 | Option Exercise | 55.76 | 7,000 | 390,310 | 13,898 | May 20 07:15 PM | | HENDERSON REBECCA M | Director | May 17 | Sale | 105.72 | 8,421 | 890,300 | 5,477 | May 20 07:15 PM | | Patton Cynthia M | SVP & CCO | May 16 | Option Exercise | 54.58 | 3,544 | 193,437 | 18,986 | May 17 05:42 PM | | Patton Cynthia M | SVP & CCO | May 16 | Sale | 105.01 | 3,544 | 372,148 | 15,442 | May 17 05:42 PM | | BIONDI FRANK | Director | May 14 | Option Exercise | 56.50 | 10,000 | 564,950 | 39,780 | May 16 05:38 PM | | PELHAM JUDITH C | Director | May 14 | Option Exercise | 55.47 | 25,000 | 1,386,650 | 48,149 | May 16 05:42 PM | | PELHAM JUDITH C | Director | May 14 | Sale | 108.25 | 25,000 | 2,706,165 | 23,149 | May 16 05:42 PM | | BIONDI FRANK | Director | May 14 | Sale | 108.43 | 10,000 | 1,084,318 | 29,780 | May 16 05:38 PM | | de Carbonnel Francois | Director | Apr 30 | Option Exercise | 54.74 | 10,000 | 547,400 | 21,930 | May 02 06:26 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Option Exercise | 50.44 | 10,000 | 504,400 | 64,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Sale | 107.02 | 10,000 | 1,070,191 | 54,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Option Exercise | 58.43 | 10,000 | 584,300 | 66,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Sale | 107.99 | 10,000 | 1,079,872 | 56,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Option Exercise | 54.69 | 8,662 | 473,725 | 65,973 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Sale | 107.95 | 8,662 | 935,029 | 57,311 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 24 | Sale | 105.95 | 6,924 | 733,565 | 58,311 | Apr 26 05:33 PM | | de Carbonnel Francois | Director | Mar 13 | Option Exercise | 54.74 | 10,000 | 547,400 | 17,805 | Mar 14 06:18 PM | | BALTIMORE DAVID | Director | Feb 28 | Option Exercise | 74.89 | 5,000 | 374,450 | 35,526 | Mar 01 05:31 PM | | BALTIMORE DAVID | Director | Feb 28 | Sale | 92.94 | 886 | 82,345 | 30,526 | Mar 01 05:31 PM | | HERRINGER FRANK C | Director | Feb 26 | Option Exercise | 74.89 | 5,000 | 374,450 | 21,262 | Feb 26 06:20 PM | | PELHAM JUDITH C | Director | Feb 08 | Option Exercise | 62.55 | 5,000 | 312,750 | 26,304 | Feb 11 07:56 PM | | PELHAM JUDITH C | Director | Feb 08 | Sale | 86.94 | 5,000 | 434,715 | 21,304 | Feb 11 07:56 PM | | Bradway Robert A | President and CEO | Dec 20 | Option Exercise | 64.56 | 40,000 | 2,582,400 | 141,711 | Dec 20 06:34 PM | | BALTIMORE DAVID | Director | Dec 10 | Option Exercise | 50.78 | 16,000 | 812,480 | 46,526 | Dec 12 06:40 PM | | BALTIMORE DAVID | Director | Dec 10 | Sale | 89.00 | 6,800 | 605,220 | 30,526 | Dec 12 06:40 PM |
|
|
|
|
|
|
